Adverse Outcome Pathways can drive non-animal approaches for safety assessment
暂无分享,去创建一个
Melvin E Andersen | Alan Boobis | Fiona Sewell | Maurice Whelan | Natalie Burden | Ian Kimber | Thomas H Hutchinson | M. Andersen | A. Boobis | M. Cronin | M. Whelan | T. Hutchinson | J. Chipman | I. Kimber | T. Hutchinson | Mark T D Cronin | F. Sewell | N. Burden | J Kevin Chipman | J. Chipman
[1] E. Crouch,et al. A Weight-of-evidence analysis of the cancer dose-response characteristics of 2,3,7,8-tetrachlorodibenzodioxin (TCDD). , 2006, Toxicological sciences : an official journal of the Society of Toxicology.
[2] M E Meek,et al. New developments in the evolution and application of the WHO/IPCS framework on mode of action/species concordance analysis , 2013, Journal of applied toxicology : JAT.
[3] J. M. Kelley,et al. Assessing the risks of exposures to multiple chemicals with a common mechanism of toxicity: how to cumulate? , 2000, Regulatory toxicology and pharmacology : RTP.
[4] Chanita Kuseva,et al. Towards AOP application--implementation of an integrated approach to testing and assessment (IATA) into a pipeline tool for skin sensitization. , 2014, Regulatory toxicology and pharmacology : RTP.
[5] J. Bailar,et al. Toxicity Testing in the 21st Century: A Vision and a Strategy , 2010, Journal of toxicology and environmental health. Part B, Critical reviews.
[6] M Younes,et al. IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. , 2001, Regulatory toxicology and pharmacology : RTP.
[7] Steven K. Gibb. Toxicity testing in the 21st century: a vision and a strategy. , 2008, Reproductive toxicology.